“Navigare Ventures is pleased to continue supporting ProteomEdge in this next phase,” says Elin Almstedt, Principal at Navigare Ventures. “The successful development of DiscoveryEdge600 and the company’s growing commercial traction highlight both execution strength and market relevance. We remain confident in the team’s ability to deliver on its vision and drive continued growth.”

ProteomEdge, founded in 2023 by researchers from the Human Protein Atlas program and SciLifeLab in Stockholm, develops proprietary mass spectrometry-based solutions for absolute protein quantification, enabling precise and scalable measurement of clinically relevant proteins. ProteomEdge’s product portfolio supports biomarker research and translational applications in blood-based proteomics.

Commercial expansion

The proceeds will support the company’s commercial expansion and the rollout of DiscoveryEdge 600, an expanded offering for absolute protein quantification by mass spectrometry. 

Henrik Everberg, CEO, ProteomEdge

“This financing gives us the resources to accelerate our commercial expansion. With DiscoveryEdge 600 now launched, we are focused on broadening customer access to high-precision absolute protein quantification,” says Henrik Everberg, CEO of ProteomEdge. 

“The fact that we are securing additional funding from the same committed investors demonstrates a shared long-term belief in ProteomEdge. This investment enables us to further strengthen our product portfolio and scale our commercial presence globally,” says Professor Mathias Uhlén, Co-founder and Chairman of the Board.